Fostamatinib disodium (also known as R-788; R-935788; brand name: Tavalisse) is the prodrug form of the active metabolite R406. It is an orally bioactive and selective Syk inhibitor with anti-inflammatory activity. It inhibits Syk kinase with IC50 of 41 nM in a cell-free assay. As of 2018, Fostamatinib gained FDA approval to treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP). Fostamatinib strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Fostamatinib has displayed anti-inflammatory and immunomodulating activities.
Physicochemical Properties
Molecular Formula | C23H24FN6NA2O9P |
Molecular Weight | 624.42 |
Exact Mass | 624.112 |
CAS # | 1025687-58-4 |
Related CAS # | Fostamatinib;901119-35-5;Fostamatinib disodium hexahydrate;914295-16-2 |
PubChem CID | 25008120 |
Appearance | White to yellow solid powder |
LogP | 3.53 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 9 |
Heavy Atom Count | 42 |
Complexity | 893 |
Defined Atom Stereocenter Count | 0 |
InChi Key | HSYBQXDGYCYSGA-UHFFFAOYSA-L |
InChi Code | InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2 |
Chemical Name | sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate |
Synonyms | Fostamatinib disodium hexahydrate; R788; R 788; R-788 sodium; Tamatinib Fosdium, R-935788; R935788; R-935788; R 935788; R935788 sodium. Fostamatinib sodium, prodrug of R-406. |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro |
|
||
ln Vivo | In Louvain rats, fostamatinib (R788) is highly bioavailable and rapidly absorbed. Following a single oral dose of R788 10 mg/kg or R406 20 mg/kg, the following results were observed after one hour: t1/2 = 4.2 hours; AUC0-16 hrs = 10618 ng*h/mL and 30650 ng*h/mL, respectively; Cmax = 2600 ng/mL and 6500 ng/mL, respectively. The complete conversion of R788 to R406 was shown by the absence of prodrug in plasma [1]. | ||
Animal Protocol |
|
||
References |
[1]. Fostamatinib Disodium. Drugs Future. 2011;36(4):273. [2]. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. [3]. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8. |
||
Additional Infomation |
Fostamatinib Disodium Anhydrous is the anhydrous form of fostamatinib disodium, an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis. Fostamatinib Disodium is an orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis. See also: Fostamatinib (has active moiety). Drug Indication Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. |
Solubility Data
Solubility (In Vitro) |
|
|||
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 0.5% CMC+0.25% Tween 80,pH6.5:30 mg/mL  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6015 mL | 8.0074 mL | 16.0149 mL | |
5 mM | 0.3203 mL | 1.6015 mL | 3.2030 mL | |
10 mM | 0.1601 mL | 0.8007 mL | 1.6015 mL |